MARKET

BYSI

BYSI

BeyondSpring
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.68
+0.06
+0.57%
Opening 15:52 12/04 EST
OPEN
10.68
PREV CLOSE
10.62
HIGH
10.83
LOW
10.59
VOLUME
332.86K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
9.38
MARKET CAP
418.03M
P/E (TTM)
-5.2471
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Do Hedge Funds Love BeyondSpring, Inc. (BYSI)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Insider Monkey · 5d ago
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 5d ago
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
-- BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium
GlobeNewswire · 11/25 12:04
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
* BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT03294577) at the 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. The Company will also present three posters about the PROTECTIVE-1 Trial and PROTECTIVE-2 Trial at the San Antonio Breast Cancer Symposium (SABCS) being held virtually December 8-11, 2020.Details for the ASH Poster PresentationTitle:   Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts) Abstract: 817 Session: 201\. Granulocytes, Monocytes, and Macrophages: Poster I Hematology Disease Topics & Pathways: Therapies, Combinations, Clinically relevant Date/Time: Saturday, December 5, 2020 from 7:00 a.m.-3:30 p.m. PST Presenter: Douglas W. Blayney, M.D. (Stanford University)     Details for the SABCS Poster PresentationsTitle:   Plinabulin and Pegfilgrastim (Plin+Peg) versus Peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain Publication : PS11-15 Date/Time: starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand) Presenter: Douglas W. Blayney, M.D. (Stanford University)     \-----------       Title: Protective-2 (bpi-2358-106): a confirmatory trial to demonstrate superiority of the plinabulin+pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts) Publication : OT-06-02 Date/Time: starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand) Presenter: Douglas W. Blayney, M.D. (Stanford University)       \-----------       Title: Differential efficacy of Pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of Docetaxel (Doc) chemotherapy-induced neutropenia (CIN) Publication : PS13-34 Date/Time:  starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand) Presenter: Douglas W. Blayney, M.D. (Stanford University)     \-----------       Title: Superior Protection Against Profound Neutropenia with the Plinabulin/Pegfilgrastim (Plin/Peg) Combination versus Pegfilgrastim (Peg) Monotherapy In Breast Cancer (BC) Patients Receiving TAC Chemotherapy: Final Results from Protective-2 (BPI-2358-106)     Date/Time: starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand) Presenter: Douglas W. Blayney, M.D. (Stanford University)     About BeyondSpring BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.Investor Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 617-430-7577 arr@lifesciadvisors.com Media Contact: Darren Opland, Ph.D. LifeSci Communications +1 646-627-8387 darren@lifescicomms.com
GlobeNewswire · 11/25 01:59
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020. Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer of BeyondSpring will participate in a fireside chat session beginning at approximately 9:15 am ET.A live webcast and replay of the webcast will be accessible on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentation" in the Investors section.About BeyondSpring BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.Investor Contact:Ashley Robinson LifeSci Advisors arr@lifesciadvisors.com 617-430-7577Media Contact:Darren Opland, Ph.D. LifeSci Communications darren@lifescicomms.com 646-627-8387
GlobeNewswire · 11/23 21:01
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.
GlobeNewswire · 11/23 21:01
ZTO Express Cayman, Chindata Group Holdings leads premarket losers' pack
X Financial (XYF) -33%.MeiraGTx Holdings (MGTX) -10% on public offering pricing at $12.85/share.Tantech Holdings (TANH) -9%.BeyondSpring (BYSI) -9% on public offering pricing at $10.0/share.Chindata Group Holdings (CD) -7% on Q3 earnings release.Phoenix Tree Holdings (DNK) -7%.ZTO
Seekingalpha · 11/19 13:23
BeyondSpring slides 9% on public offering pricing at $10.0/share
BeyondSpring (BYSI) slips 9% premarket, after pricing its previously announced public offering of 7.5M shares at $10.0/share, for gross proceeds of ~$75M.The offering is expected to close by November 23.
Seekingalpha · 11/19 13:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BYSI. Analyze the recent business situations of BeyondSpring through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BYSI stock price target is 35.50 with a high estimate of 43.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 2.25M
% Owned: 5.75%
Shares Outstanding: 39.14M
TypeInstitutionsShares
Increased
19
123.83K
New
9
-178.01K
Decreased
16
189.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+1.59%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Huang Lan
Chief Financial Officer
Liu Dongheng
Chief Operating Officer
Richard Daly
Executive Vice President/Director
Ramon Mohanlal
Chief Scientific Officer
G. Kenneth Lloyd
Chief Scientific Officer
James Tonra
Other
Gordon Schooley
Independent Director
Patrick Fabbio
Independent Director
Matthew Kirkby
Independent Director
Quanqi Song
Independent Director
Yanbin Xie
Independent Director
Daniel Zabrowski
Independent Director
Ying Zhao
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BYSI
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Beyondspring Inc stock information, including NASDAQ:BYSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BYSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BYSI stock methods without spending real money on the virtual paper trading platform.